Study: Nirsevimab, Abrysvo provide similar protection against RSV
WASHINGTON — Nirsevimab and maternal vaccination offered similar levels of protection against respiratory syncytial virus among newborns, according to recently published data.
Previous studies have shown that nirsevimab (Beyfortus, AstraZeneca/Sanofi) and the maternal vaccine (Abrysvo, Pfizer) protect infants from hospitalization and other complications of RSV disease, but the literature is light on comparisons.
“Directly comparing these effectiveness estimates is challenging. The people who are getting one vs. the other are different,” Karen B. Jacobson, MD, MPH, a research scientist at the